: Crispr Therapeutics’ stock soars as FDA-panel meeting raises hopes sickle-cell-disease drug will be approved

Crispr Therapeutics' stock rallied 12% Wednesday amid hopes a treatment for sickle-cell disease will win regulatory approval.